Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Gut microbiome diversity measures for metabolic conditions: a systematic scoping review

View ORCID ProfileChatpol Samuthpongtorn, View ORCID ProfileTanawin Nopsopon, View ORCID ProfileKrit Pongpirul
doi: https://doi.org/10.1101/2021.06.25.21259549
Chatpol Samuthpongtorn
1Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chatpol Samuthpongtorn
Tanawin Nopsopon
2Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tanawin Nopsopon
Krit Pongpirul
2Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4Bumrungrad International Hospital, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Krit Pongpirul
  • For correspondence: doctorkrit{at}gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective Evidence on the association between the gut microbiome and metabolic conditions has been increasing during the past decades. Unlike the straightforward identification of beneficial non-pathogenic bacteria as a potential probiotic for clinical use, the analysis of gut microbiome diversity is more complex and required a better understanding of various measures. We aim to summarize an elaborated list of gut microbiome diversity measures.

Design Systematic search was conducted in three databases: PubMed, Embase, and Cochrane Central Register of Clinical Trials for randomized controlled trials, quasi-experimental and observational studies for the relationship between gut microbiota and metabolic diseases published in 2019 with the English language.

Results The measurement methods of alpha diversity and beta diversity were explored. Of 5929 potential studies, 47 were included in the systematic review (14632 patients). Of 13 alpha diversity measures, the Shannon index was the most commonly used in 37 studies (78.7%), followed by Chao1 index (19 studies), Operational Taxonomic Unit (OTU) richness (15 studies), Simpson index (13 studies), and Abundance-based Coverage Estimators (ACE) index (10 studies). Of 2 beta diversity measures, the UniFrac was the most commonly used in 24 studies (unweighted 17 studies and weighted 16 studies), followed by Bray-Curtis dissimilarity (16 studies).

Conclusion Various measurement of gut microbiome diversity have been used in the literature. All measurements have unique characteristics, advantages, and disadvantages which lead to different usage frequency. The measures were chosen considering cost, simplicity, and types of research.

What is already known on this subject?

  • ▸ Alpha diversity, including Shannon index diversity, chao1 diversity, etc., is the average species diversity within a habitat type at a local scale while beta-diversity, such as Bray-Curtis dissimilarity and UniFrac, indicates the differentiation between microbial communities from different environments.

  • ▸ Alpha- and beta-diversity are the two most diverse measures of gut microbiota diversity with no consensus on which measurement methods should be used in metabolic condition study.

What are the new findings?

  • ▸ Distinct characteristics, advantages, and disadvantages of each microbiome diversity measurement method lead to a variety of usage frequencies in metabolic condition studies. Shannon diversity is the most widely used alpha diversity while there is no predilection for beta diversity.

How might it impact on clinical practice in the foreseeable future?

  • ▸ Further researchers on metabolic condition with microbiome diversity measurement will have impartial evidence on which measurement methods are most rationally appropriate for their studies regarding simplicity, cost, and efficacy.

INTRODUCTION

Gut microbiota are microorganisms that live in several areas of the body, especially in the gastrointestinal tract. The number of human microbiota, including bacteria, fungus, and virus is approximately 1,000,000,000 - 10,000,000,000 microbial cells, with the ratio of microbial cells to human cells being 1:1.1,2 The dominant bacterial phyla in the human gastrointestinal tract are Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria.3 Current research has found associations between microbiota and systemic diseases, particularly type I and type II diabetes, obesity, and metabolic syndrome which related with immune response processes.4

Nowadays, the identification of dominant microbial communities is increasing with the invention of high throughput sequencing technology. The most important and widely used diversities are alpha-diversity and beta-diversity.5 Alpha diversity, including Shannon index diversity, chao1 diversity, etc., is the average species diversity within a habitat type at a local scale while beta-diversity, such as Bray-Curtis dissimilarity and Unifrac, indicates the differentiation between microbial communities from different environments.6 Both diversities consider two aspects of a community: the number of different organisms in a sample, and the range of abundances for each one.7

Many researchers have found the relationship between gut microbiota and metabolic diseases by diversity analysis.8 However, there was no systematic study focused on the most widely used method for diversity measurement of the association between gut microbiota and metabolic diseases. This systematic scoping review aimed to discuss and compare the measurement methods of microbiome diversities that are widely used in current research.

MATERIALS AND METHODS

Registration of protocol

This study was conducted following the recommendations of the Preferred Reporting Items of Systematic Reviews and Meta-Analyses Extension for Scoping Review (PRISMA-ScR) statement. We registered the systematic review with OSF The Open Science Framework (registration: osf.io/ux2fs).

Data sources and searches

PubMed, Embase, and Cochrane Central Register of Clinical Trials were used to search for articles published in 2019 in the English language. The terms “gastrointestinal microbiome”, “gut microbiome”, “microbiota”, and “microflora” were used in combination with “diversity”, “richness”, “evenness”, and “dissimilarity” as the keywords for literature search along with their synonyms. The search strategy is presented in detail in the online supplemental appendix 1. Additionally, the reference lists of included articles were searched, as well as related citations from other journals via Google Scholar.

Study selection

For this systematic scoping review, we worked with an information specialist to design an appropriate search strategy to identify original peer-reviewed articles of randomized controlled trials, quasi-experimental, and observational studies evaluating gut microbiome diversity in patients with a diagnosis of metabolic disease including metabolic syndrome, diabetes mellitus, hypertension, dyslipidemia, obesity, and nonalcoholic fatty liver disease (NAFLD). Article screening was done by two independent reviewers (CS and TN) for eligible studies. Discrepancies between two reviewers were resolved by consensus.

Data extraction

Data extraction was done by two independent reviewers (CS and TN) for published summary gut microbiome diversity index. Discrepancies between two reviewers were resolved by consensus. We extracted the following data: (1) study characteristics (authors, study type, journal name, contact information, country, and funding), (2) patients characteristics (sample size, type of metabolic disease, and mean age), (3) outcomes (measurement methods of alpha and beta diversity of gut microbiome) as well as any other relevant information. All relevant text, tables, and figures were examined for data extraction. We contacted the authors of the study with incompletely reported data. If the study authors did not respond within 14 days, we conducted analyses using the available data.

Data synthesis and analysis

The primary outcome was measurement methods of alpha and beta diversity of gut microbiome. We synthesized the overall usage of gut microbiome diversity index whether alpha and beta diversities had been measured in included studies and which index had been used. We then provided subgroup analyses based on study design, type of metabolic disease, geographical location, and country income.

RESULTS

Study selection

The database search identified 5,929 potential records. After removing duplicates, 4,119 titles passed the initial screen, and 535 theme-related abstracts were selected for further full-text articles assessed for eligibility (figure 1). A total of 488 were excluded as the following: 338 non peer-reviewed, 65 wrong outcomes, 25 protocol, 22 wrong publication year, 8 duplicate, 8 in vitro, 7 wrong population, 6 review articles, 4 letter to editor, 3 non-English, and 2 editorial. 47 studies were eligible for the data synthesis.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Flow chart diagram presenting the study selection with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines

Study characteristics

Of 47 included studies, there were 33 observational studies,9-41 nine randomized controlled trials,42-50 and five quasi-experimental studies (table 1).51-55 The number of patients per study ranged from 12 to 6,627, with a total of 14,632 patients. The mean age of patients varied from day of life 3 to 69 years old. There were 28 studies focused on obesity,3,11,12,16,18,22,24-28,30-34,36,38,39,43,44,46,49-53,55 12 studies on type II diabetes mellitus,3,10,14,15,17,21,26,40,43,45,47,55 four studies on hypertension,13,24,37,40 four studies on NAFLD,22,33,38,41 three studies on metabolic syndrome,31,48,51 three studies on gestational diabetes mellitus,19,20,29 two studies on dyslipidemia,23,42 and a study on type I diabetes mellitus.9

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of Included Studies

According to WHO region, there were 21 studies conducted in Western Pacific Region,8,9,11-24,31,32,41,46,52 14 studies in European Region,27-30,33,42-44,47,48,51,53-55 10 studies in Region of the Americas,25,34-40,45,50 and two studies conducted in Eastern Mediterranean Region.26,49 According to the World Bank,56 there were 27 studies conducted in high-income countries,9,11,27-36,38-44,47,48,50,51,53-55,57 19 in upper-middle income countries,10,12-25,30,45,49,52 and one in low-middle income countries.26

Gut microbiome diversity measures

Of 47 included studies, there were 35 studies reported both alpha and beta diversities, 12 studies reported alpha diversity only, and no study reported beta diversity only. Of 13 alpha diversity measures, the Shannon index was the most commonly used in 37 studies (78.7%),10-24,26,28-36,38,40,41,44-48,50,52,53,57 followed by Chao1 index (19 studies),10-13,15-18,23,24,27,29,30,32,35,42,43,48,52 Operational Taxonomic Unit (OTU) richness (15 studies),9,10,12,13,17,25-28,34,35,49,50,52,53 Simpson index (13 studies),12,13,15-17,20,23,30,31,46,49,52,55 Abundance-based Coverage Estimators (ACE) index (10 studies),12,13,15,17,18,20,30,32,52,54 Observed species (9 studies),13-15,17,18,20,29,36,52 Faith’s Phylogenetic diversity (7 studies),18,36,39,41,47,51,52 Phylogenetic diversity (5 studies),10,16,27,55,58 Good’s coverage (3 studies),12,13,18 Pielou’s evenness index (2 studies),24,27 Amplicon Sequence Variant (ASV) richness (2 studies),41,44 inversed Simpson index (2 studies),9,34 and Fisher alpha index (1 study).34

Of 2 beta diversity measures, the UniFrac was the most commonly used in 24 studies including unweighted UniFrac (17 studies),12,14,18,20,21,25-27,29,33-35,39,41,45,52,57 and weighted UniFrac (16 studies),12,13,16-18,20,25,26,34,35,37,41,44,48,51,53 followed by Bray-Curtis dissimilarity (16 studies).11,16,17,19,20,23,31,38,40-44,47,49,55 The summary result was shown in table 2 and result for each included study was provided in online supplemental appendix 2.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Gut microbiome diversity index usage in metabolic disease articles

Study design and gut microbiome diversity measures

Most common microbiome alpha-diversity measures for observational studies and randomized controlled trials were Shannon diversity in 28 observational studies (84.8%),10-24,26,28-31,33-38,40,41 and 7 RCTs (77.8%) respectively 43-48,50 Most common microbiome alpha-diversity measures for quasi-experimental were Shannon diversity,52,53 ACE index,52,54 Simpson index,52,55 and Faith’s Phylogenetic diversity in 2 studies (40%).51,52 Good’s coverage (3 studies),12,13,18 and Pielou’s evenness index (2 studies) were reported only in observational studies.27,52

Most common microbiome beta-diversity measures were different among study designs. For observational studies, unweighted Unifrac was most common with reported in 45.5% of included observational studies,12,14,18,20,21,25-27,29,33-35,37,39,41 Bray-Curtis dissimilarity for randomized controlled trials (55.6%),42-44,48,49 and weighted Unifrac for quasi-experimental studies (40%).51,53

Type of metabolic diseases and gut microbiome diversity measures

Most common microbiome alpha-diversity for all metabolic diseases was Shannon diversity. Most common microbiome beta-diversity measures for obesity and type II diabetes mellitus were weighted Unifrac (39.3%),12,16,17,25,26,34,35,44,51,53,57 and Bray-Curtis dissimilarity (33.3%) respectively.17,43,47,55

Geographical location and gut microbiome diversity measures

Most common microbiome alpha-diversity for studies in Western Pacific, European, and America Regions was Shannon diversity. Most common microbiome alpha-diversity for Eastern Mediterranean Region was OTU richness. Good’s coverage (3 studies) were used only in Western Pacific Region.12,13,18

Most common microbiome beta-diversity measures for Western Pacific, European and America were Bray-Curtis dissimilarity (38.1%),11,16,17,19,20,23,31,41 Bray-Curtis dissimilarity (35.7%),42-44,47,55 and unweighted Unifrac (60%) respectively.25,34,35,37,39,45 For microbiome beta-diversity measures for Eastern Mediterranean, all beta-diversity were equal in number (1 study, 50%).

Country income and gut microbiome diversity measures

Most common microbiome alpha-diversity for all type of country incomes was Shannon diversity. Amplicon Sequence Variant (ASV) richness (2 studies),41,44 and inversed Simpson index (2 studies) were both used in only HICs.29,36 Good’s coverage (3 studies) were used only in UMICs.12,13,18 There was a variation of most common microbiome beta-diversity measures among different country incomes. For HICs, Bray-Curtis dissimilarity was the most common beta diversity measure (37%),11,31,38,40-44,47,55 unweighted Unifrac for UMICs (42.1%),12,14,18,20-22,25,45,52 and both weighted and unweighted Unifrac for LMIC (100%).26

DISCUSSION

To our knowledge, this is the first systematic review evaluating the choice of gut microbiome diversity measurements in patients with metabolic conditions. The systematic review process identified 47 articles that met the inclusion and exclusion criteria. A meta-analysis was not performed due to the purpose of this study to identify the usage of gut microbiome diversity measurement in metabolic diseases studies. The result suggested that there were variations in measures of gut microbiome diversity in the metabolic disease literatures. For alpha-diversity, there were 13 different measurement methods used for the analysis of gut microbiota. The Shannon index was the most commonly used which presented in 37 studies (78.7%) while other methods including Chao1 index, Operational Taxonomic Unit (OTU) richness, Simpson index, Faith’s Phylogenetic diversity, and Abundance-based Coverage Estimators (ACE) index were used only 20-40%. For beta-diversity, the UniFrac was the most commonly used which assessed in 24 studies (unweighted 17 studies and weighted 16 studies), followed by Bray-Curtis dissimilarity (16 studies). All beta-diversity measures were used in a similar quantity.

Alpha diversity measures the diversity within a sample diversity and is based on the relative abundance of taxa; for example, species or OTUs.59 Alpha diversity are used to identify the richness (number of taxonomic groups), evenness (distribution of abundances of the groups), or both. There are three subtypes of alpha diversity by purpose of estimation including richness estimators, richness and evenness estimators, and phylogenetic richness estimators. The difference between these estimators was shown in online supplemental table 1. Species richness refers to the number of different species present in a community while evenness compares the uniformity of the population of the species (figure 2).

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

Community A and community B have the same species richness, five species each. The organisms in community A are more evenly distributed than in community B

Of all included studies, Shannon diversity was the most common alpha diversity measurement. Shannon diversity is an example of the richness and evenness estimators which the value of diversity increases both when the number of species increases and when evenness increases. It is a measurement of entropy and the uncertainty of the sampling outcome. Shannon diversity also contemplates the relative abundances of different species.60 The advantages of Shannon diversity are simplicity and appropriateness for the community dominant by two or three species. However, Shannon diversity weighs more on species richness which causes measure of the character of the species abundance distribution (evenness) less sensitive.

Another richness and evenness estimator is Simpson’s diversity. The advantage of Simpson’s diversity is simplicity while the drawback is insensitivity of the species richness measurement. Due to simplicity and ability to measure both richness and evenness, Shannon diversity and Simpson’s diversity are widely used in all studies.58

Another type of the estimators is the richness estimator which includes OTU richness, Chao1 index, and ACE index. OTU richness is defined as the count of different species represented in a community. Similar to Shannon and Simpson’s diversity, the advantage of OTU richness is simplicity which makes OTU richness in top three of alpha diversity measurement usage. However, the disadvantage of OTU richness is sensitivity to sample size. In our studies, Chao1 index was used in 19 studies (40.4%) and ACE index in 10 studies (21.3%). Richness estimators evaluate the total richness of a community.61 Chao1 and ACE have been developed to estimate richness from abundance data. They are the indicators of species richness that is sensitive to rare OTUs. Chao1 is based on the theory that rare species provide the most information about the number of missing species which is useful for rare species and performs accurately if the sample size is reasonably large. Therefore, Chao1 index is particularly useful for the low-abundance species while the drawback is underestimation of rich and highly heterogeneous species.

Finally, phylogenetic diversity (PD) is defined as the connecting of all organisms in a phylogenetic tree which estimates diversity across a tree and provides a phylogenetic analog of taxonomic diversity.62 PD provides a convenient, evolutionary measure of diversity that does not depend on the ability to identify species count which ultimately leads to a complex and relatively stable community of microorganisms.63 However, the limitation is lack of sequence data for the large majority of species which requires a molecular laboratory with proper facilities, thus the cost is inevitably highed.64

Beta-diversity is the measure for differences between samples from different groups. The overall community composition and structure are identified by this measure. Beta-diversity in our research including Unifrac distance and Bray-Curtis dissimilarity are similar in usage quantities. “UniFrac” considers the phylogenetic relationships between the microbes found in two samples (Similar to phylogenetic diversity) which provides a convenient measure of diversity that does not depend on the ability to identify species count.65 It estimates differences between samples or groups based on phylogenetic distance. Unifrac distance is divided into unweighted and weighted Unifrac. Unweighted UniFrac is the fraction of branch lengths between all microbes in both samples that are different between the samples.65,66 Weighted UniFrac is similar to unweighted UniFrac but takes the abundances of microbes in the samples into account. Weighted UniFrac is largely impacted by the abundances of the microbes while unweighted UniFrac does not take abundance into account. Both unweighted Unifrac and weighted Unifrac are used to determine whether communities were significantly different. Unweighted Unifrac is sensitive to detect microbial richness changes in rare species while weighted Unifrac can incorporate the abundance information and reduce the rare species’ contribution. However, both measures should not be used as a distance metric for multivariate statistical analyses.66,67

Bray-Curtis dissimilarity shows the microbes’ abundances which are shared between two samples. Bray-Curtis dissimilarity quantifies the dissimilarity between two samples or groups ranged from 0 to 1 which is not a true distance. For example, if both samples have the same number of microbes at the same abundance, their dissimilarity will equal zero. On the other hand, the dissimilarity will equal 1 if two samples have definitely no shared microbes. The benefit of Bray-Curtis dissimilarity is that it gives more weight to common species. Moreover, Bray-Curtis dissimilarity is simple and doesn’t make assumptions about genetic relationships.68

There were several limitations in this systematic scoping review. First, this systematic scoping review aims to provide evidence on the usage of gut microbiome diversity measurement in metabolic diseases studies, thus meta-analysis is not planned to perform. Second, this study focused on the gut microbiome diversity measures in patients with metabolic conditions only. The generalizability should be considered when applying the results in studies on other diseases.

In conclusion, this systematic scoping review and meta-analysis provided the first evidence on the gut microbiome Diversity Measures for Metabolic Conditions. Alpha-diversity and beta-diversity are innovative tools for gut microbiota analysis. Various measurement of gut microbiome diversity have been used in the literature. All measurements have unique characteristics, advantages, and disadvantages which lead to different usage frequency. The measures were chosen considering cost, simplicity, and types of research.

Data Availability

All data relevant to the study are included in the article or uploaded as supplementary information.

Contributors

CS, and KP conceived and designed the research. CS and TN performed data acquisition, analyzed and interpretated data, and drafted the manuscript. KP made critical revisions related to important intellectual content of the manuscript. All authors have read and approved the final version of manuscript.

Funding

No funding.

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

The study required no Ethics Committee approval as long it is a systematic review study and no human subject was directly involved.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material

Supplemental appendix 1. Full search strategy

Supplemental appendix 2. Measurement methods for each included study

Supplemental table 1. Estimator characteristics

Acknowledgement

The authors are thankful to the Prince Mahidol Award Youth Program and Professor Nijasri C. Suwanwela for their research and academic assistance, as well as Miss Pim Sermsaksasithorn for providing mental support.

Reference

  1. 1.↵
    Kim BS, Jeon YS, Chun J. Current status and future promise of the human microbiome. Pediatr Gastroenterol Hepatol Nutr 2013;16(2):71–9. doi: 10.5223/pghn.2013.16.2.71 [published Online First: 2013/09/07]
    OpenUrlCrossRefPubMed
  2. 2.↵
    Kho Z, Lal S. The Human Gut Microbiome - A Potential Controller of Wellness and Disease. Front Microbiol 2018;9:1835. doi: 10.3389/fmicb.2018.01835 [published Online First: 2018/08/30]
    OpenUrlCrossRefPubMed
  3. 3.↵
    Rinninella E, Raoul P, Cintoni M, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019;7(1) doi: 10.3390/microorganisms7010014 [published Online First: 2019/01/13]
    OpenUrlCrossRefPubMed
  4. 4.↵
    Pang SQ, Luo ZT, Wang CC, et al. Effects of Dioscorea polystachya ‘yam gruel’ on the cognitive function of diabetic rats with focal cerebral ischemia-reperfusion injury via the gut-brain axis. J Integr Neurosci 2020;19(2):273–83. doi: 10.31083/j.jin.2020.02.69
    OpenUrlCrossRef
  5. 5.↵
    Wagner B, Grunwald G, Zerbe G, et al. On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities. Front Microbiol 2018;9:1037. doi: 10.3389/fmicb.2018.01037 [published Online First: 2018/06/07]
    OpenUrlCrossRef
  6. 6.↵
    Walters K, Martiny J. Alpha-, beta-, and gamma-diversity of bacteria varies across habitats. PLoS One 2020;15(9):e0233872. doi: 10.1371/journal.pone.0233872 [published Online First: 2020/09/24]
    OpenUrlCrossRef
  7. 7.↵
    Youssef NH, Ashlock-Savage KN, Elshahed MS. Phylogenetic diversities and community structure of members of the extremely halophilic Archaea (order Halobacteriales) in multiple saline sediment habitats. Appl Environ Microbiol 2012;78(5):1332–44. doi: 10.1128/aem.07420-11 [published Online First: 2011/12/20]
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Shen G, Wu J, Ye B, et al. Gut Microbiota-Derived Metabolites in the Development of Diseases. Can J Infect Dis Med Microbiol 2021;2021:6658674. doi: 10.1155/2021/6658674 [published Online First: 2021/01/29]
    OpenUrlCrossRef
  9. 9.↵
    Harbison J, Roth-Schulze A, Giles L, et al. Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study. Pediatric diabetes 2019;20(5):574–83. doi: 10.1111/pedi.12865 [published Online First: 2019/05/14]
    OpenUrlCrossRefPubMed
  10. 10.↵
    Liu T, Chen X, Xu Y, et al. Gut microbiota partially mediates the effects of fine particulate matter on type 2 diabetes: Evidence from a population-based epidemiological study. Environment international 2019;130:104882. doi: 10.1016/j.envint.2019.05.076 [published Online First: 2019/06/16]
    OpenUrlCrossRef
  11. 11.↵
    Robinson H, Barrett H, Gomez-Arango L, et al. Ketonuria Is Associated with Changes to the Abundance of Roseburia in the Gut Microbiota of Overweight and Obese Women at 16 Weeks Gestation: A Cross-Sectional Observational Study. Nutrients 2019;11(8) doi: 10.3390/nu11081836 [published Online First: 2019/08/11]
    OpenUrlCrossRef
  12. 12.↵
    Lv Y, Qin X, Jia H, et al. The association between gut microbiota composition and BMI in Chinese male college students, as analysed by next-generation sequencing. The British journal of nutrition 2019;122(9):986–95. doi: 10.1017/s0007114519001909 [published Online First: 2019/08/10]
    OpenUrlCrossRef
  13. 13.↵
    Mushtaq N, Hussain S, Zhang S, et al. Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension. International journal of molecular medicine 2019;44(2):513–22. doi: 10.3892/ijmm.2019.4235 [published Online First: 2019/06/08]
    OpenUrlCrossRef
  14. 14.↵
    Nuli R, Azhati J, Cai J, et al. Metagenomics and Faecal Metabolomics Integrative Analysis towards the Impaired Glucose Regulation and Type 2 Diabetes in Uyghur-Related Omics. Journal of diabetes research 2019;2019:2893041. doi: 10.1155/2019/2893041 [published Online First: 2019/12/13]
    OpenUrlCrossRef
  15. 15.↵
    Nuli R, Cai J, Kadeer A, et al. Integrative Analysis Toward Different Glucose Tolerance-Related Gut Microbiota and Diet. Frontiers in endocrinology 2019;10:295. doi: 10.3389/fendo.2019.00295 [published Online First: 2019/06/14]
    OpenUrlCrossRef
  16. 16.↵
    Qiu D, Xia Z, Deng J, et al. Glucorticoid-induced obesity individuals have distinct signatures of the gut microbiome. BioFactors (Oxford, England) 2019;45(6):892–901. doi: 10.1002/biof.1565 [published Online First: 2019/10/08]
    OpenUrlCrossRef
  17. 17.↵
    Tao S, Li L, Li L, et al. Understanding the gut-kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition. Acta Diabetol 2019;56(5):581–92. doi: 10.1007/s00592-019-01316-7 [published Online First: 2019/03/20]
    OpenUrlCrossRef
  18. 18.↵
    Wang F, Bai R, Yan W, et al. Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients. Exp Ther Med 2019;17(3):2268–78. doi: 10.3892/etm.2019.7200 [published Online First: 2019/03/15]
    OpenUrlCrossRef
  19. 19.↵
    Wu Y, Bible P, Long S, et al. Metagenomic analysis reveals gestational diabetes mellitus-related microbial regulators of glucose tolerance. Acta diabetologica 2020;57(5):569–81. doi: 10.1007/s00592-019-01434-2 [published Online First: 2019/12/11]
    OpenUrlCrossRef
  20. 20.↵
    Xu Y, Zhang M, Zhang J, et al. Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation. American journal of physiology Endocrinology and metabolism 2020;319(2):E247–e53. doi: 10.1152/ajpendo.00266.2019 [published Online First: 2020/01/01]
    OpenUrlCrossRef
  21. 21.↵
    Zhang F, Wang M, Yang J, et al. Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine 2019;66(3):485–93. doi: 10.1007/s12020-019-02041-5 [published Online First: 2019/08/15]
    OpenUrlCrossRef
  22. 22.↵
    Zhao Y, Zhou J, Liu J, et al. Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease. Frontiers in pediatrics 2019;7:518. doi: 10.3389/fped.2019.00518 [published Online First: 2020/01/11]
    OpenUrlCrossRef
  23. 23.↵
    Zheng W, Ma Y, Zhao A, et al. Compositional and functional differences in human gut microbiome with respect to equol production and its association with blood lipid level: a cross-sectional study. Gut pathogens 2019;11:20. doi: 10.1186/s13099-019-0297-6 [published Online First: 2019/06/07]
    OpenUrlCrossRef
  24. 24.↵
    Zuo K, Li J, Xu Q, et al. Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production. Clinical cardiology 2019;42(8):710–19. doi: 10.1002/clc.23195 [published Online First: 2019/05/18]
    OpenUrlCrossRef
  25. 25.↵
    de la Cuesta-Zuluaga J, Mueller N, Álvarez-Quintero R, et al. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. Nutrients 2018;11(1) doi: 10.3390/nu11010051 [published Online First: 2018/12/29]
    OpenUrlCrossRef
  26. 26.↵
    Salah M, Azab M, Ramadan A, et al. New Insights on Obesity and Diabetes from Gut Microbiome Alterations in Egyptian Adults. Omics : a journal of integrative biology 2019;23(10):477–85. doi: 10.1089/omi.2019.0063 [published Online First: 2019/10/08]
    OpenUrlCrossRef
  27. 27.↵
    Olsson L, Poitou C, Tremaroli V, et al. Gut microbiota of obese subjects with Prader-Willi syndrome is linked to metabolic health. Gut 2020;69(7):1229–38. doi: 10.1136/gutjnl-2019-319322 [published Online First: 2019/10/16]
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Seck E, Senghor B, Merhej V, et al. Salt in stools is associated with obesity, gut halophilic microbiota and Akkermansia muciniphila depletion in humans. International journal of obesity (2005) 2019;43(4):862–71. doi: 10.1038/s41366-018-0201-3 [published Online First: 2018/09/13]
    OpenUrlCrossRef
  29. 29.↵
    Ponzo V, Ferrocino I, Zarovska A, et al. The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM). PloS one 2019;14(12):e0226545. doi: 10.1371/journal.pone.0226545 [published Online First: 2019/12/17]
    OpenUrlCrossRef
  30. 30.↵
    Belkova N, Nemchenko U, Pogodina A, et al. Composition and Structure of Gut Microbiome in Adolescents with Obesity and Different Breastfeeding Duration. Bulletin of experimental biology and medicine 2019;167(6):759–62. doi: 10.1007/s10517-019-04617-7 [published Online First: 2019/10/28]
    OpenUrlCrossRef
  31. 31.↵
    Koo S, Chu C, Khoo J, et al. A pilot study to examine the association between human gut microbiota and the host’s central obesity. JGH open : an open access journal of gastroenterology and hepatology 2019;3(6):480–87. doi: 10.1002/jgh3.12184 [published Online First: 2019/12/14]
    OpenUrlCrossRef
  32. 32.↵
    Lin B, Lin W, Huang C, et al. Changes of gut microbiota between different weight reduction programs. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2019;15(5):749–58. doi: 10.1016/j.soard.2019.01.026 [published Online First: 2019/04/03]
    OpenUrlCrossRef
  33. 33.↵
    Astbury S, Atallah E, Vijay A, et al. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut microbes 2020;11(3):569–80. doi: 10.1080/19490976.2019.1681861 [published Online First: 2019/11/08]
    OpenUrlCrossRef
  34. 34.↵
    Faucher M, Greathouse K, Hastings-Tolsma M, et al. Exploration of the Vaginal and Gut Microbiome in African American Women by Body Mass Index, Class of Obesity, and Gestational Weight Gain: A Pilot Study. Am J Perinatol 2020;37(11):1160–72. doi: 10.1055/s-0039-1692715 [published Online First: 2019/06/27]
    OpenUrlCrossRef
  35. 35.↵
    Fei N, Bernabé B, Lie L, et al. The human microbiota is associated with cardiometabolic risk across the epidemiologic transition. PloS one 2019;14(7):e0215262. doi: 10.1371/journal.pone.0215262 [published Online First: 2019/07/25]
    OpenUrlCrossRef
  36. 36.↵
    Stanislawski M, Dabelea D, Lange L, et al. Gut microbiota phenotypes of obesity. NPJ biofilms and microbiomes 2019;5(1):18. doi: 10.1038/s41522-019-0091-8 [published Online First: 2019/07/10]
    OpenUrlCrossRefPubMed
  37. 37.↵
    Maskarinec G, Hullar M, Monroe K, et al. Fecal Microbial Diversity and Structure Are Associated with Diet Quality in the Multiethnic Cohort Adiposity Phenotype Study. J Nutr 2019;149(9):1575–84. doi: 10.1093/jn/nxz065 [published Online First: 2019/06/13]
    OpenUrlCrossRef
  38. 38.↵
    Schwimmer J, Johnson J, Angeles J, et al. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157(4):1109–22. doi: 10.1053/j.gastro.2019.06.028 [published Online First: 2019/07/01]
    OpenUrlCrossRefPubMed
  39. 39.↵
    Shen N, Caixàs A, Ahlers M, et al. Longitudinal changes of microbiome composition and microbial metabolomics after surgical weight loss in individuals with obesity. Surg Obes Relat Dis 2019;15(8):1367–73. doi: 10.1016/j.soard.2019.05.038 [published Online First: 2019/07/13]
    OpenUrlCrossRef
  40. 40.↵
    Sun S, Lulla A, Sioda M, et al. Gut Microbiota Composition and Blood Pressure. Hypertension (Dallas, Tex : 1979) 2019;73(5):998–1006. doi: 10.1161/hypertensionaha.118.12109 [published Online First: 2019/03/25]
    OpenUrlCrossRef
  41. 41.↵
    Kim H, Joo E, Cheong H, et al. Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases. Journal of clinical medicine 2019;8(8) doi: 10.3390/jcm8081089 [published Online First: 2019/07/28]
    OpenUrlCrossRef
  42. 42.↵
    Conterno L, Martinelli F, Tamburini M, et al. Measuring the impact of olive pomace enriched biscuits on the gut microbiota and its metabolic activity in mildly hypercholesterolaemic subjects. European journal of nutrition 2019;58(1):63–81. doi: 10.1007/s00394-017-1572-2 [published Online First: 2017/11/11]
    OpenUrlCrossRef
  43. 43.↵
    Horvath A, Leber B, Feldbacher N, et al. Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. European journal of nutrition 2020;59(7):2969–83. doi: 10.1007/s00394-019-02135-w [published Online First: 2019/11/16]
    OpenUrlCrossRef
  44. 44.↵
    Kern T, Blond M, Hansen T, et al. Structured exercise alters the gut microbiota in humans with overweight and obesity-A randomized controlled trial. International journal of obesity (2005) 2020;44(1):125–35. doi: 10.1038/s41366-019-0440-y [published Online First: 2019/08/31]
    OpenUrlCrossRef
  45. 45.↵
    Medina-Vera I, Sanchez-Tapia M, Noriega-López L, et al. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes & metabolism 2019;45(2):122–31. doi: 10.1016/j.diabet.2018.09.004 [published Online First: 2018/09/30]
    OpenUrlCrossRef
  46. 46.↵
    Uemura M, Hayashi F, Ishioka K, et al. Obesity and mental health improvement following nutritional education focusing on gut microbiota composition in Japanese women: a randomised controlled trial. European journal of nutrition 2019;58(8):3291–302. doi: 10.1007/s00394-018-1873-0 [published Online First: 2018/12/14]
    OpenUrlCrossRef
  47. 47.↵
    van Bommel E, Herrema H, Davids M, et al. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. Diabetes & metabolism 2020;46(2):164–68. doi: 10.1016/j.diabet.2019.11.005 [published Online First: 2019/12/10]
    OpenUrlCrossRef
  48. 48.↵
    Velikonja A, Lipoglavšek L, Zorec M, et al. Alterations in gut microbiota composition and metabolic parameters after dietary intervention with barley beta glucans in patients with high risk for metabolic syndrome development. Anaerobe 2019;55:67–77. doi: 10.1016/j.anaerobe.2018.11.002 [published Online First: 2018/11/06]
    OpenUrlCrossRef
  49. 49.↵
    Ejtahed H, Tito R, Siadat S, et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. European journal of endocrinology 2019;180(3):165–76. doi: 10.1530/eje-18-0826 [published Online First: 2018/12/13]
    OpenUrlCrossRef
  50. 50.↵
    Karvonen A, Sordillo J, Gold D, et al. Gut microbiota and overweight in 3-year old children. International journal of obesity (2005) 2019;43(4):713–23. doi: 10.1038/s41366-018-0290-z [published Online First: 2018/12/21]
    OpenUrlCrossRef
  51. 51.↵
    Bakker G, Schnitzler J, Bekkering S, et al. Oral vancomycin treatment does not alter markers of postprandial inflammation in lean and obese subjects. Physiological reports 2019;7(16):e14199. doi: 10.14814/phy2.14199 [published Online First: 2019/08/20]
    OpenUrlCrossRef
  52. 52.↵
    Zhou T, Chen J, Chen Y, et al. Ligustrum robustum Intake, Weight Loss, and Gut Microbiota: An Intervention Trial. Evid Based Complement Alternat Med 2019;2019:4643074. doi: 10.1155/2019/4643074 [published Online First: 2019/05/22]
    OpenUrlCrossRef
  53. 53.↵
    Kellerer T, Brandl B, Büttner J, et al. Correction to: Impact of Laparoscopic Sleeve Gastrectomy on Gut Permeability in Morbidly Obese Subjects. Obesity surgery 2021 doi: 10.1007/s11695-021-05439-1 [published Online First: 2021/05/01]
    OpenUrlCrossRef
  54. 54.↵
    Romo-Vaquero M, Cortés-Martín A, Loria-Kohen V, et al. Deciphering the Human Gut Microbiome of Urolithin Metabotypes: Association with Enterotypes and Potential Cardiometabolic Health Implications. Molecular nutrition & food research 2019;63(4):e1800958. doi: 10.1002/mnfr.201800958 [published Online First: 2018/11/25]
    OpenUrlCrossRef
  55. 55.↵
    Frost F, Storck L, Kacprowski T, et al. A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of Collinsella in obese type 2 diabetics: A pilot study. PloS one 2019;14(7):e0219489. doi: 10.1371/journal.pone.0219489 [published Online First: 2019/07/19]
    OpenUrlCrossRefPubMed
  56. 56.↵
    World Bank Country and Lending Groups 2021 [Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups],.
  57. 57.↵
    Maskarinec G, Hullar M, Monroe K, et al. Fecal Microbial Diversity and Structure Are Associated with Diet Quality in the Multiethnic Cohort Adiposity Phenotype Study. The Journal of nutrition 2019;149(9):1575–84. doi: 10.1093/jn/nxz065 [published Online First: 2019/06/13]
    OpenUrlCrossRef
  58. 58.↵
    Kim B, Shin J, Guevarra R, et al. Deciphering Diversity Indices for a Better Understanding of Microbial Communities. J Microbiol Biotechnol 2017;27(12):2089–93. doi: 10.4014/jmb.1709.09027 [published Online First: 2017/10/17]
    OpenUrlCrossRefPubMed
  59. 59.↵
    McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 2013;8(4):e61217. doi: 10.1371/journal.pone.0061217 [published Online First: 2013/05/01]
    OpenUrlCrossRefPubMed
  60. 60.↵
    Lemos L, Fulthorpe R, Triplett E, et al. Rethinking microbial diversity analysis in the high throughput sequencing era. J Microbiol Methods 2011;86(1):42–51. doi: 10.1016/j.mimet.2011.03.014 [published Online First: 2011/04/05]
    OpenUrlCrossRefPubMed
  61. 61.↵
    Shen T-J, Chao A, Lin C-F. Predicting the Number of New Species in Further Taxonomic Sampling. Ecology 2003;84(3):798–804.
    OpenUrlCrossRefWeb of Science
  62. 62.↵
    Faith DP. Conservation evaluation and phylogenetic diversity. Biological Conservation 1992;61(1):1–10. doi: https://doi.org/10.1016/0006-3207(92)91201-3
    OpenUrlCrossRefWeb of Science
  63. 63.↵
    Garson J, Plutynski A, Sarkar S. The Routledge Handbook of Philosophy of Biodiversity: Taylor & Francis 2016.
  64. 64.↵
    O’Dwyer J, Kembel S, Green J. Phylogenetic diversity theory sheds light on the structure of microbial communities. PLoS Comput Biol 2012;8(12):e1002832. doi: 10.1371/journal.pcbi.1002832 [published Online First: 2013/01/04]
    OpenUrlCrossRefPubMed
  65. 65.↵
    Lozupone C, Hamady M, Knight R. UniFrac--an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformatics 2006;7:371. doi: 10.1186/1471-2105-7-371 [published Online First: 2006/08/09]
    OpenUrlCrossRefPubMed
  66. 66.↵
    Chen J, Bittinger K, Charlson E, et al. Associating microbiome composition with environmental covariates using generalized UniFrac distances. Bioinformatics 2012;28(16):2106–13. doi: 10.1093/bioinformatics/bts342 [published Online First: 2012/06/20]
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    Lozupone C, Lladser M, Knights D, et al. UniFrac: an effective distance metric for microbial community comparison. Isme j 2011;5(2):169–72. doi: 10.1038/ismej.2010.133 [published Online First: 2010/09/10]
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    Morgan X, Huttenhower C. Chapter 12: Human microbiome analysis. PLoS Comput Biol 2012;8(12):e1002808. doi: 10.1371/journal.pcbi.1002808 [published Online First: 2013/01/10]
    OpenUrlCrossRefPubMed
Back to top
PreviousNext
Posted July 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Gut microbiome diversity measures for metabolic conditions: a systematic scoping review
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Gut microbiome diversity measures for metabolic conditions: a systematic scoping review
Chatpol Samuthpongtorn, Tanawin Nopsopon, Krit Pongpirul
medRxiv 2021.06.25.21259549; doi: https://doi.org/10.1101/2021.06.25.21259549
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Gut microbiome diversity measures for metabolic conditions: a systematic scoping review
Chatpol Samuthpongtorn, Tanawin Nopsopon, Krit Pongpirul
medRxiv 2021.06.25.21259549; doi: https://doi.org/10.1101/2021.06.25.21259549

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)